AVITA’s RECELL® System trial on DFU patients yields favorable results
Category: #health  By Mateen Dalal  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA’s RECELL® System trial on DFU patients yields favorable results

The 26-week observational study included 16 subjects at three different hospitals in the UK

Global regenerative medicine company AVITA Medical has recently announced that their open-label study of the latest RECELL® System, conducted on 16 subjects with diabetic foot ulcers (DFUs) who had been unresponsive to standard care treatments, yielded promising results.

Apparently, the RECELL® Autologous Cell Harvesting Device uses a small portion of a patient’s own skin to formulate Spray-On Skin™ Cells at the point-of-care.

Mr. Tawqeer Rashid, Consultant Vascular and Endovascular Surgeon at the Manchester Royal Infirmary, was quoted saying that there was a definite need to find new cures for chronic conditions like DFUs, since they deeply impact the patients’ lives.

Reportedly, Rashid made the announcement at the 11th annual Japanese Society of Limb Salvage & Podiatric Medicine conference held in Japan on June 28 & 29, 2019. He also added that the RECELL® System showed favorable potential in speeding up the healing of DFUs.

Citing reliable sources, the 26-week observational study included 16 subjects at three different hospitals in the UK, including Manchester Royal Infirmary, Northwick Park Hospital and Kings College Hospital. Subjects under observation suffered from chronic DFUs ranging from 5 to 33 sq.cm, with variable depths, with and without infection, inclusive of tendon and bone exposure, that had not been responsive to various standard treatments.

The patients were then treated with the RECELL® System which was applied over the affected area.

Evidently, the study generated encouraging results, including an 83% average wound size reduction in all the patients at the end of the 26th week and 100% recovery in half of the patients with an average period of 14 weeks. The treatment seems to have provided a satisfactory safety profile and excellent patient and physician scores were reported following the study. 

AVITA Medical CEO Michael Perry stated that successful conclusions from the study demonstrate RECELL® System’s versatility and the company is committed towards exploring how their new regenerative technology can be further developed for advance patient care. 

Source credit: https://www.avitamedical.com/uploads/pdf/PR-20190701.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...

Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
By Mateen Dalal

The healthcare company will showcase its drugs in the ASTRO annual meeting 2019 that could help offer improved efficiency and confidence in treatment delivery. Akesis, Inc., a hospital and healthcare company based in the U.S. that offers innovative...

Adverum reveals positive results from Phase 1 trial of ADVM-022
Adverum reveals positive results from Phase 1 trial of ADVM-022
By Mateen Dalal

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD. Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announc...